WWL70 manufacturers
- WWL70
-
- $55.00
-
2026-07-14
- CAS:947669-91-2
- Purity: 98.53%
- Supply Ability: 10g
|
| Product Name: | WWL70 | | Synonyms: | WWL70;N-Methyl-N-[[3-(4-pyridinyl)phenyl]methyl]-4'-(aminocarbonyl)[1,1'-biphenyl]-4-ylcarbamicacidester;4-CARBAMOYL-[1,1-BIPHENYL]-4-YL METHYL(3-(PYRIDIN-4-YL)BENZYL)CARBAMATE;WWL 70; WWL70; WWL-70.;[4-(4-carbamoylphenyl)phenyl] N-methyl-N-[(3-pyridin-4-ylphenyl)methyl]carbamate;Carbamic acid, N-methyl-N-[[3-(4-pyridinyl)phenyl]methyl]-, 4'-(aminocarbonyl)[1,1'-biphenyl]-4-yl ester;Inhibitor,MAGL,Monoacylglycerol lipase,WWL70,WWL 70,inhibit,WWL-70;4'-Carbamoyl-[1,1'-biphenyl]-4-yl methyl(3-(pyridin-4-yl)benzyl)carbamate | | CAS: | 947669-91-2 | | MF: | C27H23N3O3 | | MW: | 437.49 | | EINECS: | | | Product Categories: | | | Mol File: | 947669-91-2.mol |  |
| | WWL70 Chemical Properties |
| storage temp. | Store at +4°C | | solubility | DMSO : 17.33 mg/mL (39.61 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) | | form | Powder | | color | White to off-white |
| | WWL70 Usage And Synthesis |
| Uses | WWL70 is a selective inhibitor of ABHD6. | | Biological Activity | In mice, WWL70 guards against neuropathic pain stimulated by chronic constriction injury. It decreases the inflammatory response in the ipsilateral spinal cord, dorsal root ganglion (DRG) and sciatic nerve. WWL70 is considered as an anti-inflammatory therapeutic agent, th at has the ability to prevent the synthesis of PGE2 (prostaglandin E2) and PGE2-G (PGE2-glyceryl ester).', 'WWL70 is a selective inhibitor of α/β-hydrolase domain-containing 6 (ABHD6), a serine hydrolase th at acts as an alternative hydrolase of the endocannabinoid 2-arachidonoylglycerol (2-AG). It has an IC50 value of 55-70 nM and 90-95% inihibition of ABDH6. WWL70 hs been used in a variety of studies as an ABHD6 antagonist. It was shown to rescue impaired function of mGluR5 signaling, resulting in pain inhibition in arthritic rats. WWL70 was also used to show th at ABHD6 is involved in brown adipose function and white adipose browning, and is a potential therapeutic target for obesity and type 2 diabetes. | | in vivo | Although post-treatment with WWL70 at 5 mg/kg does not have any effect, treatment with WWL70 at 10 mg/kg improves the performance significantly. WWL70 treatment improves motor coordination of traumatic brain injury (TBI) mice in a concentration dependent manner. The latency to fall in animals treated with WWL70 at 5 mg/kg increases from 74.92±4.8 to 99.57±5.21 on day 3 (p<0.01) and from 87.32±4.42 to 100.14±3.56 on day 7 (p<0.05) post-injury when compare with the vehicle-TBI groups. At 10 mg/kg, WWL70 treatment improves motor coordination starting on day 1 post-injury. WWL70 treatment completely restores the ability of TBI mice to continuously alternate arms during Y maze exploration (69.67±4.98 %)[3]. |
| | WWL70 Preparation Products And Raw materials |
|